We recently compiled a list of the Top 10 Must-See AI News Updates for Investors. In this article, we are going to take a ...

Adial Pharmaceuticals (ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United States Patent and Trademark ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Royalty Pharma (RPRX – Research Report), ...

Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies. You can obtain detailed information about the use of cookies ...

CNW/ - Canada Pension Plan Investment Board (CPP Investments) ended its third quarter on December 31, 2024, with net assets ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Pablo Legorreta, CEO, highlighted strong 2024 performance, with Portfolio Receipts reaching $2.8 billion, at the high end of guidance and representing 13% growth in Royalty Receipts. He noted this ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Class A shares underperformed the MSCI ACWI ex USA Index. During the quarter, we initiated four new positions and exited one ...

Arabian Business unveils its 2025 list of 100 Most Inspiring Women, showcasing the female leaders transforming the Middle ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

The transaction, expected to close in the first half of this year, will cost Novartis $925 million upfront with potential ...